February 9, 2014
Merck & Co. could settle thousands of lawsuits filed against them over the safety of its NuvaRing contraceptive and could pay $100mn as long as there will be enough participation from women in the agreement.
Under the agreement, the Whitehouse Station, New Jersey-based Merck denies any wrongdoing in state and federal courts, and also in some unfiled claims. The company said around 3,800 people are eligible to take part in the accord, and 95 percent of them has to participate for the deal to proceed.
NuvaRing, which is a hormonal-vaginal contraceptive that uses a mix of estrogen and progestin in a ring to prevent women from getting pregnant, was linked in a U.S. Food and Drug Administration report released in 2011 that suggested it causes elevated risk for blood clots. The product has been sold in the U.S. market since 2001.